Polyploidy

Humboldt Seed Company Debuts First High-Potency Triploid Cannabis Seeds

Retrieved on: 
Tuesday, January 30, 2024
Dark, Pollination, HSC, Cannabis, SAN, THC, Polyploidy, Genetically modified organism, Phenotype, Carbon footprint, Nutrient, Water, Disease resistance, Seed

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Humboldt Seed Company (HSC), the largest licensed cannabis seed seller in California, today announced the release of its OG Kush Triploid and Donutz Triploid cannabis seeds to the U.S. market.

Key Points: 
  • High-THC triploid seed release expands Humboldt Seed Company's catalog of novel, terpene-rich strains.
  • SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Humboldt Seed Company (HSC), the largest licensed cannabis seed seller in California, today announced the release of its OG Kush Triploid and Donutz Triploid cannabis seeds to the U.S. market.
  • "This seed release has been a long time coming," said Benjamin Lind, co-founder and chief science officer of Humboldt Seed Company.
  • "I had a chance to compare the triploid and diploid plants at the Humboldt Seed Company 2023 phenotype hunt.

Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress

Retrieved on: 
Wednesday, November 8, 2023
Spectrum, German Cancer Research Center, Aneuploidy, CMA, MCA, OEM, Sale, Genomics, DSM-IV codes, OGM, NMPA, WES, SVS, IVD, Publication, Rare, Polyploidy, CRISPR, Medtech, International Cancer Genome Consortium, Doctor of Philosophy, GAAP, Acquisition, Research, Poster, Karyotype, Lobotomy Corporation, Genome, Nature Communications, National Medical Products Administration, SNV calling from NGS data, Hospital, Annual general meeting, CGC, Workflow, Bone marrow, KT, CFO, Cancer, ASD, Total, VIA, IPSC, Chromosomal deletion syndrome, SAN, DNA, Outline, Beauty salon, Cryptocurrency, Video game, Vaccine, Management, Medical device, Pharmaceutical industry

Publications featuring OGM increased 61% from the third quarter of 2022 to the third quarter of 2023, including a total of 47 human-focused publications.

Key Points: 
  • Publications featuring OGM increased 61% from the third quarter of 2022 to the third quarter of 2023, including a total of 47 human-focused publications.
  • GAAP gross margin for the third quarter of 2023 was 30%, compared to 25% from the third quarter of 2022.
  • Third quarter 2023 non-GAAP¹ gross margin was 32%, compared to 25% from the third quarter of 2022.
  • Third quarter 2023 non-GAAP operating expense was $31.8 million, compared to $26.3 million in the third quarter of 2022 and $34.6 million in the second quarter of 2023.

Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis

Retrieved on: 
Thursday, September 28, 2023
Polyploidy, Reflex, FISH, CMA, Genomics, Fluorescence, KT, Spectrum, Aneuploidy, Research, DSM-IV codes, Karyotype, MCA, ASD, SAN, In situ hybridization, WGS, Lobotomy Corporation, OGM, Audit, Dietary supplement

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA).

Key Points: 
  • SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA).
  • Additionally, KT and FISH are needed as a reflex when researchers must confirm a translocation or locate a duplication.
  • The gap between long-read sequencing and CMA is even greater than the gap between short-read WGS and CMA.
  • It is important for the research community to have a benchmarking study comparing OGM to CMA, especially for genetic disorders, since OGM has a comparatively cost-effective workflow with simple interpretation and analysis.

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Retrieved on: 
Monday, July 17, 2023
Science, Women, Other Science, Research, Health, Medical Devices, Genetics, Consumer, Chromosome, Polyploidy, Probability, Ion, ART, Infertility, Multimedia, Thermo Fisher Scientific, IVF, ICSI, Antibiotics, Dietary supplement, Birth control

To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific today launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.

Key Points: 
  • To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific today launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
  • The Ion ReproSeq PGT-A Kit * and the Ion AmpliSeq Polyploidy Kit * mark the first research use reproductive health assays available on the Ion Torrent Genexus Integrated Sequencer*, delivering complete workflows from sample to result for aneuploidy analysis.
  • “Building on Thermo Fisher’s existing reproductive health offerings, today’s launch brings the benefits of next-generation sequencing to more research labs with the potential of rapid, in-house testing and analysis,” said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific.
  • “Considering the far-reaching implications for those struggling with infertility, researchers must have reliable and accurate testing available to advance the fertility field and ultimately improve reproductive health for all.

Investigating the placenta: Discovery from Stowers Scientists shows why this often-overlooked organ should be given more attention

Retrieved on: 
Wednesday, June 7, 2023
Dai, DNA, Human, Pregnancy, Placenta, Mortal Kombat, Stowers Institute for Medical Research, Fetus, Parent, Embryo, Indira Gandhi Institute of Development Research, Research, Attention, Polyploidy, Cell, DNA replication, Chromosome, Place of birth, Preterm birth, Immune system, Pre-eclampsia, Cell cycle, Mouse, Placentalia, Birth, Medical research, Genome, Disease, Dietary supplement, Baking, Birth control, Vaccine, Development

"I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."

Key Points: 
  • "I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."
  • "Following birth, the placenta is often tossed in the medical wastebin," explained Stowers Investigator Jennifer Gerton, Ph.D. "This makes it the most overlooked, undervalued, and understudied organ in reproductive science."
  • "The placenta may be the most polyploid organ in a pregnant female mouse, but more research into polyploidy is warranted."
  • "I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."

Bionano Announces Two Publications from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing including the First Peer-Reviewed Publication on the Multi-Site Evaluation of OGM Against SOC

Retrieved on: 
Thursday, March 2, 2023
DSM-IV codes, SOC, Doctor of Philosophy, Spectrum, Phenotype, Genomics, Clinical trial, OGM, University, University of Rochester, Polyploidy, Workflow, FMR1, Patient, Aneuploidy, SVS, Medical college, Genetic disorder, FACMG, Standard of care, Publication, SAN, University of Rochester Medical Center, Diagnosis, Chromosomal translocation, CNV, ASD, Intellectual disability, AOH, Dietary supplement, Pharmaceutical industry, Medical device, Mail order, Cryptocurrency, Genetic distance, 7p22.1 microduplication syndrome

describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows:

Key Points: 
  • describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows:
    Pre-print publication from Broeckel, et al.
  • The clinical trial is designed to compare OGM to SOC, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases.
  • A peer-reviewed publication covered an interim readout of the study, which showed OGM’s high technical performance and reproducibility across sites versus SOC analysis.
  • Key findings were reported as follows:
    The pre-print publication describes OGM performance metrics compared to SOC methods for challenging samples from diagnosed and undiagnosed rare diseases.

Bionano Genomics Announces Issuance of a U.S. Patent for Analysis of Small Nucleic Acid Fragments in Nanochannel Arrays

Retrieved on: 
Wednesday, June 29, 2022
OGM, Annual report, Lists of diseases, Patient, Biology, Monosomy, Research, Aneuploidy, Adoption, Autism, Lineagen, GLOBE, SVS, COVID-19, United States Patent and Trademark Office, Blood, Polyploidy, Nanochannel glass materials, Company, UHMW, Genomics, Neoplasm, Trisomy, U.S. Securities and Exchange Commission, Organic acid, SAN, NIPT, Technology, Private Securities Litigation Reform Act, Genome, Software, Doctor of Philosophy, DNA, Nasdaq, Patent, Medicine, Solution, Hospital Insurance and Diagnostic Services Act, Forward-looking statement, Method, Medical imaging

The patent, titled CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight (UHMW) DNA for the identification of structural variants (SVs) as part of its Saphyr system.

Key Points: 
  • The patent, titled CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight (UHMW) DNA for the identification of structural variants (SVs) as part of its Saphyr system.
  • Additionally, Bionanos portfolio includes patents directed to methods of fabricating nanochannel devices, as well as other technologies for sample processing and analysis related workflows.
  • At Bionano, we remain committed to expanding the utility of our nanochannel arrays and creating a robust patent portfolio that protects those applications.
  • Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.

United States Non-Invasive Prenatal Testing (NIPT) Market Research Report 2022: Size, Share, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 24, 2022
Health, General Health, Risk, NIPT, CAGR, The, Research, Industry, Technology, Polyploidy, Forecast, COVID-19, Medical imaging, Medical device, Growth

The Prominent Factors that are Expected to Contribute to the Growth of the United States Non-Invasive Prenatal Testing Market During the Forecast Period:

Key Points: 
  • The Prominent Factors that are Expected to Contribute to the Growth of the United States Non-Invasive Prenatal Testing Market During the Forecast Period:
    After conducting thorough research on the historical and current growth parameters, the growth prospects of the United States non-invasive prenatal testing (NIPT) market are obtained with maximum precision.
  • This new 2022 market report provides a holistic analysis of the entire United States non-invasive prenatal testing market.
  • The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States non-invasive prenatal testing market.
  • What is the total market size and forecast (until 2030) for the united states non-invasive prenatal testing market?

Bionano Genomics Announces Major Updates to Its Solve™ and Access™ Data Solutions Adding Significant New Variant Detection, Analysis and Reporting Capabilities for Optical Genome Mapping on the Saphyr® System

Retrieved on: 
Wednesday, November 3, 2021
Autism, Biology, Research, Technology, Genomics, SAN, Cancer, Genome, ISCN, International system, Fragile, IBD, Polyploidy, Lineagen, UPD, Lists of publishing companies, Family, Security (finance), U.S. Securities and Exchange Commission, OGM, Patient, Adoption, Private Securities Litigation Reform Act, SVS, Solve, AOH, Medicine, Access, Software, Hospital Insurance and Diagnostic Services Act, Annual report, Forward-looking statement, Company, CEO, COVID-19, Laboratory, Lists of diseases, SNP, Solution, Acquisition, Classification, VAF, GLOBE, Doctor of Philosophy, Medical imaging, Risk management

The updates will also enable users to visualize chromosomal AOH across the genome similarly to single nucleotide polymorphism (SNP) microarrays.

Key Points: 
  • The updates will also enable users to visualize chromosomal AOH across the genome similarly to single nucleotide polymorphism (SNP) microarrays.
  • Also as part of this release, the family of EnFocustargeted analysis panels now includes one for Fragile X, a repeast expansion disorder.
  • Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.
  • The Companys mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software.

Presentation at ASHG Showcases New Capabilities for Optical Genome Mapping with Detection of Allelic Imbalance and Absence of Heterozygosity Further Expanding Its Utility in Revealing More Clinically Relevant Variants

Retrieved on: 
Wednesday, October 20, 2021
Polyploidy, Software, AOH, Biology, Chromosome, Hospital Insurance and Diagnostic Services Act, Society, American Society of Human Genetics, Poster, Cancer, Access, Autism, Private Securities Litigation Reform Act, COVID-19, Aneuploidy, Lists of diseases, U.S. Securities and Exchange Commission, Genome, Doctor of Philosophy, Genomics, Security (finance), SNP, OGM, Lineagen, Annual report, SAN, Research, IBD, CEO, Adoption, Lists of publishing companies, Medicine, GLOBE, Patient, Forward-looking statement, Workflow, ASHG, Solution, SV, DNA, UPD, Human genetics, Zygosity, NGS, SVS, Medical imaging

These new OGM capabilities are expected to be released to Bionanos customers in upcoming versions of our Access and Solve software.

Key Points: 
  • These new OGM capabilities are expected to be released to Bionanos customers in upcoming versions of our Access and Solve software.
  • For example, some regions with AOH may be indicative of uniparental isodisomy (UPD) or regions of the genome identical by descent (IBD).
  • Measurement and representation of allelic imbalance enables OGM to detect triploidy and other chromosomal imbalances and may shed light on mosaic SVs.
  • We believe the detection of triploidy, regions associated with imprinted chromosomal disorders and IBD substantially improves the utility of OGM for clinical research applications.